Smith & Nephew plc (SNN) Stock Analysis & Investment Frameworks
Smith & Nephew plc (SNN) stock analysis on Invetso. Review Smith & Nephew plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Smith & Nephew plc Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Medical - Devices
- Country: GB
Smith & Nephew plc Key Financial Metrics
- Market Cap: $12.32B
- Revenue: $6.16B
- P/E Ratio: 19.71
- ROE: 12.25%
- ROIC: 8.85%
- Dividend Yield: 2.70%
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Smith & Nephew plc Investment Frameworks
Invetso analyzes Smith & Nephew plc (SNN) across the following frameworks:
- Smith & Nephew plc 10Y Growth Potential
- Smith & Nephew plc Scenario Analysis
- Smith & Nephew plc Risks & Opportunities
- Smith & Nephew plc Economic Moat
- Smith & Nephew plc Business Model
- Smith & Nephew plc Management
- Smith & Nephew plc SWOT Analysis
- Smith & Nephew plc Porter's 5 Forces
- Smith & Nephew plc PESTLE Analysis
- Smith & Nephew plc ESG Analysis

